Presentation and pathogenesis of B-cell lymphoid cancers associated with HIV infection

Cancers in People with HIV and AIDS: Progress and Challenges

Volumn , Issue , 2014, Pages 155-173

  Little, Richard F ^a   Pittaluga, Stefania ^b   Dunleavy, Kieron ^b  

^a Cancer Therapy Evaluation Program   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84930248230     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4939-0859-2_11     Document Type: Chapter

References (28)

1. Abayomi EA, Somers A, et al. Impact of the HIV epidemic and Anti-Retroviral Treatment policy on lymphoma incidence and subtypes seen in the Western Cape of South Africa, 2002-2009: Preliminary fi ndings of the Tygerberg Lymphoma Study Group. Transfus Apher Sci. 2011; 44(2):161-6.
2. Alizadeh AA, Eisen MB, et al. Distinct types of diffuse large B-cell lymphoma identifi ed by gene expression profi ling. Nature. 2000;403(6769):503-11.
3. Antinori A, De Rossi G, et al. Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol. 1999;17(2):554-60.
4. Besson C, Goubar A, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood. 2001;98(8):2339-44.
5. Biggar RJ, Jaffe ES, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood. 2006;108(12):3786-91.
6. Breen E, Fatahi S, et al. Elevated serum soluble CD30 precedes the development of AIDSassociated non-Hodgkin's B cell lymphoma. Tumour Biol. 2006;27(4):187-94.
7. Castillo JJ, Beltran BE, et al. The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res. 2012;36(4):413-7.
8. Chadburn A, Chiu A, et al. Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS malignancies consortium clinical trials 010 and 034. J Clin Oncol. 2009; JCO.2008.2020.5450.
9. Dunleavy K, Wilson WH. How I treat HIV-associated lymphoma. Blood. 2012;119(14):3245-55.
10. Dunleavy K, Little RF, et al. The role of tumor histogenesis, FDG-PET, and short course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115:3017-24.
11. Dunleavy K, Pittaluga S, et al. Low-intensity therapy in adult Burkitt lymphoma. New Engl J Med. 2013;369:1915-25.
12. Engels EA, Pfeiffer RM, et al. Immunologic and virologic predictors of AIDS-related non-Hodgkin lymphoma in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr. 2010;54(1):78-84.
13. Fan W, Bubman D, et al. Distinct subsets of primary effusion lymphoma can be identifi ed based on their cellular gene expression profile and viral association. J Virol. 2005;79(2):1244-51.
14. Gloghini A, Dolcetti R, et al. Lymphomas occurring specifically in HIV-infected patients: from pathogenesis to pathology. Semin Cancer Biol. 2013;23(6, Part A):457-67.
15. Greisman HA, Lu Z, et al. IgH partner breakpoint sequences provide evidence that AID initiates t(11;14) and t(8;14) chromosomal breaks in mantle cell and Burkitt lymphomas. Blood. 2012;120(14):2864-7.
16. Guech-Ongey M, Simard EP, et al. AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood. 2010.
17. Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol. 2008;8(1):22-33.
18. Lindqvist M, van Lunzen J, et al. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest. 2012;122(9):3271-80.
19. Little RF, Pittaluga S, et al. Highly effective treatment of acquired immunodeficiency syndromerelated lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101(12):4653-9.
20. Montoto S, Shaw K, et al. HIV status does not Influence outcome in patients with classical hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol. 2012;30(33):4111-6.
21. Raez L, Cabral L, et al. Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2. AIDS Res Hum Retroviruses. 1999;15(8): 713-9.
22. Rosenwald A, Wright G, et al. The use of molecular profi ling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937-47.
23. Sasakawa A, Hirase C, et al. Interleukin-8 in the pathogenesis of primary central nervous system lymphoma in association with HIV infection. Hematology. 2012;17(3):144-50.
24. Schmitz R, Young RM, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490:116-20 (advance online publication).
25. Shiels MS, Engels EA. Increased risk of histologically defi ned cancer subtypes in human immunodeficiency virus-infected individuals: Clues for possible immunosuppression-related or infectious etiology. Cancer. 2012;118:4869-76.
26. Swerdlow SH, Campo E, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: World Health Organization; 2008.
27. Uldrick TS, Polizzotto MN, et al. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood. 2011;117(26):6977-86.
28. Wilson WH, Hernandez-Ilizaliturri FJ, et al. Novel disease targets and management approaches for diffuse large B-cell lymphoma. Leuk Lymphoma. 2010;51(S1):1-10.